IDEXX Laboratories Inc (IDXX)vsMerck & Company Inc (MRK)
IDXX
IDEXX Laboratories Inc
$562.91
+0.30%
HEALTHCARE · Cap: $44.15B
MRK
Merck & Company Inc
$146.35
+3.85%
HEALTHCARE · Cap: $360.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1362% more annual revenue ($66.57B vs $4.55B). IDXX leads profitability with a 25.0% profit margin vs 4.8%. MRK appears more attractively valued with a PEG of 2.71. IDXX earns a higher WallStSmart Score of 63/100 (C+).
IDXX
Buy63
out of 100
Grade: C+
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.6%
Fair Value
$436.51
Current Price
$562.91
$126.40 premium
Margin of Safety
-73.7%
Fair Value
$83.64
Current Price
$146.35
$62.71 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 71 in profit
Strong operational efficiency at 35.0%
Safe zone — low bankruptcy risk
Keeps 25 of every $100 in revenue as profit
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Trading at 27.5x book value
Trading at 8.6x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 25.0% and operating margin at 35.0%.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : IDXX
The primary concerns for IDXX are P/E Ratio, PEG Ratio, Price/Book.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 115.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
IDXX profiles as a mature stock while MRK is a value play — different risk/reward profiles.
IDXX carries more volatility with a beta of 1.55 — expect wider price swings.
IDXX is growing revenue faster at 9.7% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
IDXX scores higher overall (63/100 vs 36/100), backed by strong 25.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?